| Literature DB >> 35901833 |
Ignace Vergote1, Antonio Gonzalez-Martin2, Domenica Lorusso3, Charlie Gourley4, Mansoor Raza Mirza5, Jean-Emmanuel Kurtz6, Aikou Okamoto7, Kathleen Moore8, Frédéric Kridelka9, Iain McNeish10, Alexander Reuss11, Bénédicte Votan12, Andreas du Bois13, Sven Mahner14, Isabelle Ray-Coquard15, Elise C Kohn16, Jonathan S Berek17, David S P Tan18, Nicoletta Colombo19, Rongyu Zang20, Nicole Concin21, Dearbhaile O'Donnell22, Alejandro Rauh-Hain23, C Simon Herrington4, Christian Marth24, Andres Poveda25, Keiichi Fujiwara26, Gavin C E Stuart27, Amit M Oza28, Michael A Bookman29.
Abstract
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical Research was held virtually in October, 2021, following published consensus guidelines. The goal of the consensus meeting was to achieve harmonisation on the design elements of upcoming trials in ovarian cancer, to select important questions for future study, and to identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and adoption of 20 statements within four topic groups on clinical research in ovarian cancer including first line treatment, recurrent disease, disease subgroups, and future trials. Unanimous consensus was obtained for 14 of 20 statements, with greater than 90% concordance in the remaining six statements. The high acceptance rate following active deliberation among the GCIG groups confirmed that a consensus process could be applied in a virtual setting. Together with detailed categorisation of unmet needs, these consensus statements will promote the harmonisation of international clinical research in ovarian cancer.Entities:
Mesh：
Year: 2022 PMID： 35901833 PMCID： PMC9465953 DOI： 10.1016/S1470-2045(22)00139-5
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 54.433